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ABSTRACT	
	
Background	
Circumsporozoite	protein	(CS)	is	the	antigenic	target	for	RTS,S,	the	most	
advanced	malaria	vaccine	to	date.	Heterologous	prime‐boost	with	the	viral	
vectors	ChAd63‐MVA	is	the	most	potent	inducer	of	T‐cells	in	humans,	
demonstrating	significant	efficacy	when	expressing	the	pre‐erythrocytic	antigen	
insert	ME‐TRAP.	We	hypothesised	that	ChAd63‐MVA	containing	CS	may	result	in	
significant,	clinical	protective	efficacy.		
	
Methods	
We	conducted	an	open‐label,	two‐site	partially	randomized	sporozoite	
controlled	human	malaria	infection	(CHMI)	study	to	compare	the	clinical	efficacy	
of	ChAd63‐MVA	CS	with	ChAd63‐MVA	ME‐TRAP.	The	study	was	registered	at:	
www.clinicaltrials.gov	(NCT01623557).		
	
Results	
1/15	(7%)	vaccinees	receiving	ChAd63‐MVA	CS	and	2/15	(13%)	vaccinees	
receiving	ChAd63‐MVA	ME‐TRAP	were	sterilely	protected	post‐CHMI.	3/15	
(20%)	vaccinees	receiving	ChAd63‐MVA	CS	and	5/15	(33%)	vaccinees	receiving	
ChAd63‐MVA	ME‐TRAP	demonstrated	a	delay	in	time	to	treatment	compared	to	
unvaccinated	controls.	In	qPCR	analyses,	ChAd63‐MVA	CS	was	estimated	to	
reduce	liver	parasite	burden	by	69‐79%,	compared	to	79‐84%	for	ChAd63‐MVA	
ME‐TRAP.		
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Conclusions	
ChAd63‐MVA	CS	does	result	in	a	reduction	in	liver	parasite	burden	but	ChAd63‐
MVA	ME‐TRAP	remains	the	most	promising	antigenic	insert	for	a	vectored	liver‐
stage	vaccine.	Detailed	analyses	of	parasite	kinetics	may	allow	detection	of	
smaller,	but	biologically	important	differences	in	vaccine	efficacy	that	can	
influence	future	vaccine	development.	
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INTRODUCTION	
	
The	worldwide	burden	of	disease	from	Plasmodium	falciparum	malaria	remains	
a	major	public	health	concern	[1],	with	approximately	207	million	cases	and	
627,000	deaths	worldwide	in	2012	[2].	The	pre‐erythrocytic	P.	falciparum	
vaccine,	RTS,S,	formed	from	fusion	of	the	circumsporozoite	(CS)	protein	to	the	
surface‐antigen	of	hepatitis	B,	is	the	most	advanced	malaria	vaccine	in	
development.	However	it	confers	only	limited,	relatively	short‐lived	protection	
in	African	infants	[3‐5].	Analysis	of	the	immunological	correlates	of	immunity	
induced	by	the	RTS,S	vaccine	suggest	that	high	levels	of	antibodies	against	CS	on	
the	sporozoite	correlate	with	protection,	with	a	possible	minor	contribution	
from	low	levels	of	induced	CD4+	T	cells	[6‐8].	Whilst	these	clinical	results	are	the	
most	effective	to	date	in	a	field	setting,	there	remains	a	need	to	improve	on	this	
limited	clinical	efficacy	[9,10],	either	through	modifications	to	RTS,S	or	by	
developing	vaccine	strategies	that	combine	numerous	antigens	or	vaccine	
platforms.		
	
Increasingly,	data	from	animal	models	and	vectored	immunisations	demonstrate	
a	correlation	between	CD8+	T	cells	and	liver‐stage	immunity,	even	in	the	absence	
of	antibodies.[11‐17]	Clinical	vaccine	development	had	been	hampered	by	the	
limited	ability	of	traditional	subunit	vaccine	strategies,	namely	adjuvanted	
protein	constructs,	to	induce	high	enough	numbers	of	antigen	specific	CD8+	T	
cells	that	may	confer	protection	[18].	However	more	recently,	adenoviral	
vectored	malaria	vaccines	administered	in	heterologous	prime‐boost	regimens	
with	an	modified	vaccinia	virus	Ankara	(MVA)	boost	have	been	shown	capable	of	
 at U
niversity of Southam
pton on N
ovem
ber 13, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
6	
inducing	good	humoral	and	T	cell	responses	that	include	high	levels	of	CD8+	T	
cells	[17‐21].	These	CD8+	T	cell	responses	have	been	associated	with	clinical	
efficacy	[17].	Given	concerns	regarding	the	effect	of	pre‐existing	immunity	on	the	
immunological	potency	of	human	adenoviruses,	simian	adenoviruses	(ChAd)	are	
being	developed	as	alternative,	potent	vectors	[22].	Indeed,	prime‐boost	
vaccination	with	ChAd63	and	MVA	expressing	the	leading	pre‐erythrocytic	
antigen,	ME‐TRAP,	is	clinically	the	most	potent	inducer	of	CD8+	T	cells	in	humans	
and	the	most	effective	malaria	vaccine	besides	RTS,S,	demonstrating	efficacy,	
defined	as	sterile	protection	or	delay,	in	8/14	(57%)	of	malaria	naïve	volunteers	
following	sporozoite	challenge	[17].			
	
Given	that	CS	is	expressed	during	both	the	sporozoite	and	liver‐stages	of	P.	
falciparum	infection	and	therefore	possibly	susceptible	to	both	humoral	and	cell	
mediated	immunity	at	both	stages,	we	assess	here	the	efficacy	of	ChAd63‐MVA	
expressing	CS.	If	effective,	this	vaccine	regimen	could	then	be	combined	with	
ChAd63‐MVA	expressing	ME‐TRAP	or	RTS,S	in	order	to	improve	clinical	efficacy.		
Following	a	phase	Ia	study	of	ChAd63‐MVA	CS	in	malaria	naïve	volunteers	where	
the	regimen	was	shown	to	be	safe	and	immunogenic	(de	Barra	et	al.	In	press),	we	
designed	a	controlled	human	malaria	infection	(CHMI)	study	[23]	using	the	
standard	five	infectious	mosquito	bite	challenge	to	compare	the	efficacy	of	
ChAd63‐MVA	CS	with	ChAd63‐MVA	ME‐TRAP.		
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METHODS	
	
Participants		
The	study	was	conducted	at	the	Centre	for	Clinical	Vaccinology	and	Tropical	
Medicine,	University	of	Oxford,	UK,	and	at	the	NIHR	Wellcome	Trust	Clinical	
Research	Facility,	part	of	the	University	of	Southampton	and	University	Hospital	
Southampton	NHS	Foundation	Trust,	UK.	The	challenge	procedure	was	
performed	as	previously	described	[24]	using	five	infectious	bites	from	P.	
falciparum	3D7‐strain	infected	Anopheles	stephensi	mosquitoes.	This	took	place	
at	the	Alexander	Fleming	Building,	Imperial	College,	London,	UK	and	mosquitoes	
were	supplied	by	the	Department	of	Entomology,	Walter	Reed	Army	Institute	of	
Research	(WRAIR),	Washington,	DC,	USA.	Healthy,	malaria‐naïve	males	and	non‐
pregnant	females	aged	18‐45	years	were	invited	to	participate	in	the	study.	All	
volunteers	gave	written	informed	consent	prior	to	participation,	and	the	study	
was	conducted	according	to	the	principles	of	the	Declaration	of	Helsinki	and	in	
accordance	with	Good	Clinical	Practice	(GCP).	There	was	no	selection	of	
volunteers	on	the	basis	of	pre‐existing	neutralizing	antibodies	to	the	ChAd63	
vector	prior	to	enrolment	(see	Supplementary	Information	for	the	full	list	of	
inclusion	and	exclusion	criteria).		
	
Ethical	&	Regulatory	Approval	
All	necessary	approvals	for	the	study	were	granted	by	the	UK	National	Research	
Ethics	Service,	Committee	South	Central	–	Oxford	A	(Ref:	12/SC/0037),	and	the	
UK	Medicines	and	Healthcare	products	Regulatory	Agency	(Ref:	
21584/0293/001‐0001).	The	study	was	additionally	reviewed	by	the	Western	
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Institution	Review	Board,	Seattle,	USA	(Ref:	20120266)	at	the	request	of	PATH	
MVI,	and	approved.	The	Genetically	Modified	Organisms	Safety	Committee	
(GMSC)	of	the	Oxford	University	Hospitals	NHS	Trust	(Reference	number	
GM462.11.65)	authorized	recombinant	vaccine	use.	The	trial	was	registered	with	
ClinicalTrials.gov	(Ref:	NCT01623557).	The	Local	Safety	Committee	provided	
safety	oversight	and	GCP	compliance	was	independently	monitored	by	an	
external	organization	(Appledown	Clinical	Research	Ltd,	Great	Missenden,	UK).	
	
ChAd63	and	MVA	Vaccines		
Generation,	manufacture	and	quality	control	monitoring	of	the	recombinant	
ChAd63	and	MVA	vectors	encoding	ME‐TRAP	&	CS	has	been	previously	
described	(de	Barra	et	al.	In	press)	[25].		
	
The	antigen	ME‐TRAP	contains	a	fusion	protein	of	a	multi‐epitope	string	(ME)	
followed	by	the	P.	falciparum	T9/96	strain	pre‐erythrocytic	thrombospondin‐
related	adhesion	protein	(TRAP)	[17].		
	
The	poor	immunogenicity	of	the	standard	full	length	CS	insert	(CSO)	previously	
used	in	clinical	trials	by	our	group	[26‐29]	suggested	that	there	may	be	an	
important	difference	in	the	intrinsic	immunogenicity	of	CSO	compared	to	the	
ME‐TRAP	insert.	Using	information	from	multiple	sources	[30‐32],	we	therefore	
designed	a	novel	CS	antigen	for	use	in	this	study	which	omits	the	extreme	C‐
terminus	of	the	protein	that	encodes	the	GPI‐anchor	sequence	and	may	down‐
modulate	CS	immunogenicity	(de	Barra	et	al.	In	press)	[33].		
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Study	Design	
This	was	a	Phase	I/IIa	open‐label,	vaccine	and	CHMI	trial	(Figure	1).	Volunteers	
chose	whether	to	participate	as	vaccinees	(Groups	1	&	2)	or	unvaccinated	
controls	undergoing	CHMI	alone	(Group	3).		Vaccinees	were	randomly	allocated	
to	Group	1	or	2.	All	vaccinations	were	administered	intramuscularly	into	the	
deltoid	with	ChAd63	and	MVA	vectored	vaccines	administered	in	alternating	
arms.	ChAd63	vectored	vaccines	were	administered	on	day	0	(D0)	and	MVA	
boost	on	D56.	Details	of	dosing,	clinical	follow‐up	and	safety	monitoring	are	
given	in	Supplementary	Information.	A	time	window	ranging	between	1	and	14	
days	was	allowed	for	vaccination	and	follow‐up	visits	post	vaccination.	CHMI	
was	performed	on	D77.	Throughout	the	paper,	study	day	refers	to	the	nominal	
time	point	for	a	group	and	not	the	actual	day	of	sampling.	
	
Ex‐vivo	interferon‐γ	(IFN‐γ)	Enzyme‐Linked	Immunosorbent	Spot	(ELIspot)	
Ex	vivo	(18‐hour	stimulation)	ELISPOT	assays	for	ME‐TRAP	and	CS	were	
performed	on	fresh	(i.e.	not	previously	frozen)	peripheral	blood	mononuclear	
cells	(PBMC)	from	blood	samples	taken	on	D0,	D14,	D28,	D56,	D63,	the	day	
before	CHMI	(C‐1),	C+7,	C+35	and	C+90.	Antigens	were	tested	in	duplicate	with	
250,000	freshly	isolated	PBMC	added	to	each	well.	See	Supplementary	
Information	for	details	of	methodology.		
	
Total	IgG	Enzyme	Linked	Immunosorbent	Assay	(ELISA)		
Antibody	responses	were	assessed	using	serum	samples	taken	on	D0,	D28,	D56,	
D63,	C‐1,	C+35	and	C+90.	Antibody	responses	to	TRAP	were	measured	by	IgG	
ELISA	performed	at	the	Jenner	Institute,	UK	(see	Supplementary	Information).	
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Antibody	responses	to	CS	were	measured	by	IgG	ELISA	performed	at	the	WRAIR	
International	Reference	Centre	for	Malaria	Serology	(see	Supplementary	
Information)[34].	
	
Parasite	Quantitative	PCR	(qPCR)	
qPCR	for	P.	falciparum	was	conducted	as	previously	described[35]	(see	
supplementary	information).		
	
Criteria	for	Malaria	Diagnosis	
Diagnosis	of	malaria	infection	following	sporozoite	CHMI	was	defined	as	positive	
thick	film	microscopy	with	at	least	one	morphologically	 ormal	malaria	
trophozoite	seen	by	one	or	more	experienced	microscopist.	qPCR	was	
simultaneously	performed,	although	investigators	directly	involved	in	clinical	
management	were	blinded	to	these	results.	In	the	case	of	volunteers	with	
positive	thick	film	microscopy	but	no	symptoms	consistent	with	P.	falciparum	
infection,	investigators	were	un‐blinded	to	the	qPCR	results	and	the	volunteer	
only	treated	if	any	preceding	samples	had	>	500	p/mL.	If	a	volunteer	described	
symptoms	or	displayed	signs	which	were	likely	to	represent	malaria	infection	in	
the	opinion	of	the	clinical	investigators	(such	as	fever,	rigors	or	severe	
symptomatology),	despite	having	a	negative	thick	film	and	in	the	absence	of	an	
alternative	cause,	they	were	un‐blinded	to	the	qPCR	results.	If	any	preceding	
samples	had	>	500	p/mL,	the	volunteer	was	treated	for	malaria.	A	vaccinee	was	
classified	as	demonstrating	a	‘delay	to	patency	/	treatment’	if	treatment	was	
started	>	2	times	the	standard	deviation	in	days	after	the	mean	time	to	treatment	
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of	unvaccinated	control	volunteers.	This	corresponds	to	clearance	of	an	
estimated	>95%	of	pre‐erythrocytic	stage	parasites[36].		
	
Statistical	Analysis	
Data	were	analyzed	using	GraphPad	Prism	version	5.03	for	Windows	(GraphPad	
Software	Inc.,	California,	USA).	Individual,	geometric	mean	(GM)	or	median	
responses	for	measurements	within	each	group	are	described.	Parasite	densities	
were	log	transformed	to	remove	skewness	with	1	added	to	each	value	to	allow	
transformation	of	zero	values.	Significance	testing	of	differences	between	groups	
used	either	a	2‐tailed	t	test	or	the	two‐tailed	Mann‐Whitney	test	(or	Kruskal‐
Wallis	test	when	comparing	more	than	two	groups)	for	 on‐parametrically	
distributed	data.	Correlations	were	assessed	using	Spearman’s	rank	correlation	
coefficient.	Time	to	treatment	was	presented	using	Kaplan‐Meier	survival	curves	
and	between	group	comparisons	were	made	using	the	log‐rank	test.		
	
RESULTS	
	
Recruitment	and	Vaccinations	
Recruitment	took	place	between	March	and	June	2012.	Thirty	healthy	malaria‐
naïve	adult	volunteers	(10	female	and	20	male)	were	enrolled	as	vaccinees	
across	two	sites	in	the	UK.	Six	further	volunteers	were	enrolled	to	undergo	CHMI	
as	unvaccinated	infectivity	controls	(5	female	and	1	male)	(Figure	1).	The	mean	
age	of	volunteers	was	26.4	years	(range	19	–	40).	Vaccinations	began	in	April	
2012,	CHMI	occurred	in	July	2012	and	all	follow‐up	visits	were	completed	by	
November	2012.	All	vaccinees	received	their	immunizations	as	scheduled.	All	
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doses	of	vaccines	were	the	same	as	those	used	in	the	comparable	Phase	Ia	
studies	(de	Barra	et	al.	In	press)	[25].	All	volunteers	underwent	CHMI	15‐21	days	
post	MVA	immunization	(i.e.	D71‐D77).	
	
Vaccine	Safety	and	Reactogenicity	(Figure	S1)	
No	unexpected	or	serious	AEs	related	to	vaccination	occurred.	The	local	and	
systemic	(Figure	S1)	reactogenicity	profile	of	each	vaccine	was	similar	to	Phase	
Ia	data	(de	Barra	et	al;	In	press)	[25].		
	
T	cell	immunogenicity	to	ChAd63‐MVA	CS	and	ME‐TRAP	determined	by	ex	
vivo	interferon‐gamma	(IFNγ)	ELISPOT	(Figure	2)	
T	cell	responses	followed	the	expected	kinetic	post	ChAd63	(de	Barra	et	al;	In	
press)[17,25,35,37,38]	with	peak	responses	seen	28	days	post	ChAd63	(Group	1	
(CS):	GM	343	spot	forming	cells	(SFC)	per	million	PBMC	(95	CI	191‐617);	Group	
2	(ME‐TRAP):	GM	553	SFC	(95	CI	330‐925)).	The	peak	T	cell	response	post	boost	
was	seen	at	D63	post	MVA	CS	for	Group	1	(GM	1017	SFC	(95	CI	630‐1641))	and	
C‐1	post	MVA	ME‐TRAP	for	Group	2	(2027	SFC	(95	CI	1472‐2792)	(Figures	2A	&	
2B).	There	was	no	significant	difference	in	T	cell	response	between	D63	and	C‐1	
for	either	group.		
	
Responses	to	both	antigens	were	well‐maintained,	with	GM	of	285	SFC	(95	CI	
156‐520)	to	CS	and	659	SFC	(95	CI	418‐1036)	to	ME–TRAP	16	weeks	post	MVA	
in	Groups	1	and	2	respectively	(Figure	2C).	T	cell	responses	among	infectivity	
controls	showed	a	GM	of	110	SFC	(95	CI	40‐304)	to	CS	and	85	SFC	(95	CI	31‐231)	
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to	ME‐TRAP	at	C‐1.	These	responses	did	not	change	significantly	during	follow	
up	(Figure	2C).	
	
Detailed	mapping	of	T	cell	responses	to	the	ME‐TRAP	antigen	are	outlined	in	
Supplementary	Information.	Detailed	mapping	of	T	cell	responses	to	CS	peptides	
was	not	performed	as	this	has	been	described	recently	in	detail	with	several	HLA	
class	I‐restricted	epitopes	[39].		
	
Antibody	immunogenicity	of	ChAd63‐MVA	CS	and	ME‐TRAP	determined	by	
enzyme‐linked	immunosorbent	assay	ELISA	(Figure	3)	
Anti‐CS	IgG	antibodies	were	measured	in	all	vaccinees	(Figure	3A).	Anti‐CS	IgG	
antibodies	were	detected	in	ME‐TRAP	vaccinees	(Group	2)	due	to	the	inclusion	
of	4	copies	of	the	NANP	repeat	from	the	CS	antigen	in	the	ME	string.	In	Group	1,	
anti‐CS	IgG	responses	peaked	21	days	post	 VA	with	a	median	of	2.1	μg/mL.	In	
Group	2,	anti‐CS	IgG	responses	also	peaked	21	days	post	MVA,	however	8/14	
volunteers	in	this	group	did	not	have	a	measurable	response,	giving	a	median	of	
0	μg/mL.	Anti‐TRAP	IgG	antibodies	were	assessed	in	Group	2	only	(Figure	3B),	
also	peaked	21	days	post	MVA	ME‐TRAP	(median	1475	ELISA	Units	(EU)).	A	
weak	relationship	between	anti‐CS	IgG	antibodies	and	CS‐specific	T	cell	
responses	at	C‐1	was	observed	in	Group	1	(r=0.5,	p=0.08,	2‐tailed	Spearman’s	
correlation,	Figure	3C).	Exposure	to	CHMI	did	not	induce	significant	levels	of	
anti‐CS	or	TRAP	antibodies	among	infectivity	controls	(Figure	3A	and	3B).		
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ChAd63‐MVA	efficacy	of	all	regimens	following	sporozoite	challenge	
Following	CHMI,	no	unexpected	AEs	occurred.	The	infectivity	controls	(Group	3)	
and	27/30	vaccinees	were	diagnosed	with	malaria.	One	volunteer	in	Group	1	
(7%)	(ChAd63‐MVA	CS)	and	2	volunteers	in	Group	2	(13%)	(ChAd63‐MVA	ME‐
TRAP)	were	sterilely	protected	(Figure	4A).	The	control	volunteers	(Group	3)	
were	diagnosed	after	a	median	time	of	10.3	days,	mean	time	of	10.5	days	(range	
8.0	–	14.0,	SD	2.2).	3	vaccinees	in	Group	1	(20%)	and	5	vaccinees	in	Group	2	
(33%)	demonstrated	a	delay	in	time	to	treatment	relative	to	controls.	There	was	
no	significant	difference	between	unvaccinated	controls	and	vaccinees	in	the	
protocol	specified	end‐point:	time	to	treatment	for	malaria	infection	(Figure	4A).	
However,	when	comparing	the	time	to	first	sample	post‐CHMI	with	either	>	500	
p/mL	(Figure	4B)	or	>	20	p/mL	(Figure	4C)	a	significant	difference	was	seen	
between	unvaccinated	controls	and	vaccinees	receiving	ChAd63‐MVA	ME‐TRAP	
(p=0.01	and	p=0.005	respectively).			
	
qPCR	Data	(Figure	5,	6)	
Primary	analysis	comparing	the	mean	parasite	density	at	C+7.5	(a	measure	of	
liver	to	blood	inoculum	(LBI)),	showed	a	significant	reduction	when	vaccinees	
receiving	ChAd63‐MVA	ME‐TRAP	but	not	ChAd63‐MVA	CS	were	compared	with	
unvaccinated	control	volunteers	(Figure	5;	p=0.01	and	p=0.08	respectively;	Mann	
Whitney	test).	The	same	comparison	performed	using	negative‐bionomial	
regression	gave	p	values	of	0.03	and	0.05,	and	a	similar	result	was	seen	when	LBI	
was	estimated	at	C+7.5	using	simple	linear	regression	(p=0.01	and	p=0.05;	Mann	
Whitney	test).	Mean	total	number	of	parasites	at	C+7.5	strongly	predicted	time	to	
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treatment	(Cox	proportional	hazards	regression;	HR=1.003974	(1.002272	–	
1.00568),	p=<0.000).		
	
Further,	exploratory	analysis	of	parasite	densities	using	area	under	the	curve	
(AUC)	analysis	showed	that	parasite	density	over	the	ﬁrst	three	replication	
cycles	in	infected	volunteers	signiﬁcantly	predicted	time	to	treatment	(Cox	
proportional	hazards	regression;	HR=1.000015	(1.000008	–	1.000022),	p<0.000)	
(Figure	6).	Over	the	first,	second	and	third	blood‐stage	replication	cycles,	there	
was	a	signiﬁcant	reduction	in	ChAd63‐MVA	ME‐TRAP	vaccinees’	parasite	
densities	measured	by	AUC	(log	[parasite	density+1])	compared	with	
unvaccinated	controls	when	sterilely	protected	vaccinees	were	included	in	the	
analysis	(cycle	1	p=0.01,	cycle	2	p=0.03	and	cycle	3	p=0.0	5,	two‐tailed	t	test).	
Parasite	densities	between	vaccinees	receiving	ChAd63	CS	and	controls	were	
significantly	reduced	over	the	first	blood‐stage	replication	cycle	only	(p=0.05	log	
[parasite	density+1]	two‐tailed	t	test).	AUC	analysis	showed	that	compared	to	
controls,	ChAd63‐MVA	ME‐TRAP	resulted	in	a	79%	reduction	in	parasitaemia	
during	cycle	1,	whilst	ChAd63‐MVA	CS	caused	a	69%	reduction. 	
	
ChAd63‐MVA	safety	of	all	regimens	following	sporozoite	challenge	(Figure	
S3)	
No	unexpected	clinical	or	laboratory	AEs	were	observed	in	vaccinees	post	CHMI	
and	there	was	no	significant	difference	in	the	number	of	AEs	related	to	CHMI	
between	groups	(p=0.72)	(Figure	S3A).	The	total	duration	of	symptoms	in	
volunteers	with	symptomatic	malaria	infection	ranged	from	1‐19	days	(median	6	
days)	with	no	significant	difference	between	groups	(p=0.33)	(Figure	S3B).	There	
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was	no	difference	between	groups	in	the	time	that	individuals	were	symptomatic	
prior	to	treatment	(p=0.43)	(Figure	S3C),	or	the	number	of	symptoms	present	at	
time	of	treatment	(p=0.65)	in	volunteers	diagnosed	with	malaria	(Figure	S3D).	
Two	of	the	33	volunteers	(6%)	diagnosed	with	malaria	post	CHMI	had	no	
symptoms	of	malaria	infection	at	diagnosis.	Of	the	volunteers	diagnosed	with	
malaria,	28	(85%)	experienced	at	least	one	AE	post	challenge	that	was	severe	in	
intensity	(Figure	S3E).	One	volunteer	in	Group	1	was	admitted	for	in‐patient	
management	of	vomiting	secondary	to	anti‐malarial	therapy	
(atovaquone/proguanil)	one	day	post	malaria	diagnosis,	and	was	discharged	the	
next	day	with	no	sequelae.	Blood	samples	taken	at	C+9,	C+35,	C+90	and	within	
24	hours	of	diagnosis	demonstrated	transient	hematological	and	biochemical	
abnormalities	at	frequencies	and	severities	expected	following	P.	falciparum	
infection	(Figure	S3F).	[40]		
	
Associations	between	immunological	outcomes	and	vaccine	efficacy	
(Figure	7)	
In	Group	1	but	not	Group	2,	IgG	antibodies	to	CS	correlated	significantly	and	
negatively	with	qPCR	densities	at	C+7.5	(Group	1:	Spearman	Rank	r=‐0.6,	p=0.03,	
Group	2:	Spearman	rank	r=‐0.3,	p=0.34)	(Figure	7A	&	7B).	A	marginal	negative	
correlation	was	seen	in	Group	2	between	IgG	antibodies	to	ME‐TRAP	and	qPCR	
at	C+7.5	(Spearman	Rank	r=‐0.5,	p=0.05)	(Figure	7C).	No	significant	correlation	
was	seen	between	IFNγ	ELISPOT	to	CS	or	ME‐TRAP	and	qPCR	at	C+7.5	for	Group	
1	or	2	(Figure	7D	&	7E)	in	concordance	with	previous	data	where	ELISPOT	
responses	did	not	correlate	with	vaccine	efficacy.[17]	Phenotyping	of	the	T	cell	
 at U
niversity of Southam
pton on N
ovem
ber 13, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
17	
responses	using	flow	cytometry	was	performed	and	will	be	reported	in	a	
subsequent	manuscript.		
	
DISCUSSION		
	
In	this	first	head‐to‐head	comparison	of	the	two	leading	pre‐erythrocytic	
antigens,	ME‐TRAP	and	CS,	delivered	in	the	same	vaccine	platform,	ME‐TRAP	has	
been	shown	to	be	associated	with	the	greater	clinical	efficacy,	sterilely	protecting	
13%	(2/15)	and	delaying	time	to	diagnosis	in	33%	(5/15)	of	vaccinees.	This	
efficacy	is	slightly	less	than	that	recently	reported	in	another	CHMI	study	of	
ChAd63‐MVA	ME‐TRAP,	[17]	despite	the	induction	of	similar,	very	high	
frequency	antigen	specific	T	cells	(peak	median	IFNγ	2027	in	this	study	v	2436	
SFC	in	the	previous	study).	Given	the	median	time	to	diagnosis	for	unvaccinated	
control	volunteers	in	this	study	was	1.5	days	shorter	than	that	of	the	previously	
reported	CHMI	study[17],	it	is	possible	that	a	larger	challenge	inoculum	in	this	
CHMI	study	could	explain	the	small,	suggested	difference	in	efficacy	results	
(there	were	no	other	differences	in	study	methodologies).	By	the	same	
reasoning,	this	could	mean	that	the	efficacy	attained	with	ChAd63‐MVA	CS	(7%	
(1/15)	sterilely	protected,	20%	(3/15)	delay	to	diagnosis)	underestimates	that	
which	may	have	been	seen	under	less	stringent	CHMI	conditions.	Indeed,	given	
that	the	‘infectious	dose’	experienced	by	individuals	in	malaria	endemic	
countries	is	generally	considerably	less	than	that	administered	in	CHMI	studies	
[23],	efficacy	may	prove	to	be	greater	in	field	studies.		
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ChAd63‐MVA	CS	induced	moderate	to	high	IFNγ	T	cell	responses	but	anti‐CS	IgG	
levels	markedly	lower	than	that	seen	with	in	a	sporozoite	CHMI	trial	assessing	
RTS,S	where	50%	(18/36)	of	vaccinees	receiving	RTS,S/AS01B	and	32%	(14/44)	
of	vaccinees	receiving	RTS,S/AS02A	were	sterilely	protected	(2.1	μg/mL	with	
ChAd63	MVA	CS	versus	144	mg/mL	with	RTS,S/AS01B	and	83mg/mL	with	
RTS,S/AS02A).	[41]	The	correlation	between	anti‐CS	antibodies	and	time	to	
treatment	suggests	this	may,	surprisingly,	be	contributing	to	the	mechanism	of	
efficacy	even	at	very	low	levels.	This	study	provides	the	first	evidence	that	sterile	
immunity	can	be	generated	with	viral	vectors	encoding	CS	alone	[41],	although	
of	note	some	sterile	efficacy	has	been	reported	using	combinations	of	DNA	and	
adenoviral	vectors	encoding	CS	and	AMA1	[18].		
	
Kaplan	Meier	analysis	of	time	to	diagnosis	between	vaccinees	and	unvaccinated	
controls	and	numerous	analyses	of	the	qPCR	data	demonstrated	significant	
efficacy	for	ChAd63‐MVA	ME‐TRAP	alone.	There	was	no	such	statistically	
significant	difference	for	the	ChAd63‐MVA	CS	vaccines	using	the	same	analysis.	
However,	the	AUC	analysis,	comparison	of	parasitaemia	at	C+7.5,	the	evidence	of	
sterile	protection	and	a	delay	to	diagnosis	in	certain	vaccinees,	all	support	the	
view	that	ChAd63‐MVA	CS	did	lead	to	a	reduction	in	the	number	of	parasites	
released	from	the	liver,	of	approximately	69‐79%,	depending	on	the	analysis.	
Given	that,	using	the	same	measures,	ChAd63‐MVA	ME‐TRAP	was	estimated	to	
reduce	liver	parasite	burden	by	79‐84%,	it	appears	that	relatively	large	
reductions	in	liver	infection	are	required	to	significantly	impact	on	clinical	
outcomes	post	mosquito	bite	CHMI,	as	suggested	previously	[34,35].	As	this	
study	shows,	it	can	be	difficult	to	quantify	the	efficacy	of	pre‐erythrocytic	
 at U
niversity of Southam
pton on N
ovem
ber 13, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
19	
vaccines	that	do	not	provide	sterile	immunity.	We	would	argue	that	given	the	
necessary,	small	numbers	of	participants	in	CHMI	studies	and	the	importance	of	
CHMI	studies	to	deselect	novel	vaccine	strategies	and	antigens	[23],	detailed	
analysis	of	qPCR	data	should	be	routinely	performed	in	order	to	ensure	that	
promising	signals	suggestive	of	clinically	important	efficacy	are	correctly	
identified.		
	
Our	data,	importantly,	compares	the	efficacy	of	ChAd63‐MVA	containing	CS	or	
ME‐TRAP	and,	together	with	previous	data	comparing	these	antigens	in	DNA‐
MVA	[25]	and	fowlpox‐MVA	regimes	[26,27,42],	support	ME‐TRAP	as	currently	
the	most	promising	liver‐stage	antigen	for	inclusion	in	a	future	multi‐stage	
vaccine.	However,	given	the	efficacy	we	have	demonstrated	here	and	the	
possibility	that	immunization	with	ME‐TRAP	and	CS	could	prove	more	
efficacious	than	either	antigen	alone,	our	next	priority	is	to	clinically	assess	the	
combination	of	ChAd63‐MVA	ME‐TRAP	and	ChAd63‐MVA	CS	in	a	CHMI	trial.		
	
We	would	suggest	that	detailed	analyses	of	parasite	kinetics	should	be	routinely	
performed	in	future	CHMI	vaccine	studies	in	order	to	allow	detection	of	smaller,	
but	biologically	important	differences	in	vaccine	efficacy	that	could	influence	
future	vaccine	development.	
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Figure	1.	Flow	chart	of	study	design	and	volunteer	recruitment.	20	
volunteers	were	excluded	following	screening	for	the	following	reasons;	
psychiatric	history	(n=3),	no	medical	screening	letter	returned	(n=3),	multiple	
medical	problems	(n=2),	alcohol	excess	(n=2),	syncope	(n=1),	connective	tissue	
disease	(n=1),	iron	deficiency	(n=1),	raised	ALT	(n=1),	poor	venous	access	(n=1),	
gastrointestinal	problems	under	investigation	(n=1),	family	history	of	heart	
disease	(n=1),	lost	to	follow	up	(n=1),	unavailable	during	challenge	(n=1),	
history	of	recreational	drug	use	(n=1).	Furthermore,	7	volunteers	withdrew	
consent	after	screening,	but	prior	to	enrolment.	All	immunizations	were	
administered	intramuscularly	with	sequential	vaccines	administered	into	the	
deltoid	of	alternating	arms.	No	enrolled	volunteers	withdrew	from	the	study	and	
all	volunteers	completed	study	visits	as	scheduled.	ChAd63	=	Simian	adenovirus	
63;	MVA	=	Modified	Vaccinia	virus	Ankara;	CS	=	Circumsporozoite;	ME‐TRAP	=	
Multiple	epitope	‐	thrombospondin‐related	adhesion	protein.	
	
Figure	2.	Antigen‐specific	T	cell	responses	to	vaccination	measured	by	IFNγ	
ELISPOT.	Kinetics	of	T	cell	responses	after	vaccination	with	ChAd63‐MVA	
encoding	either	(A)	CS	(Group	1)	or	(B)	ME‐TRAP	(Group	2).	Each	line	
represents	an	individual	volunteer.	**	=	p<0.01,	***	=	p<0.001;	Kruskall‐Wallis	
test	with	Dunn’s	multiple	comparison	test.	(C)	Median	T	cell	frequencies	for	both	
antigens	by	group.	Mean	T	cell	frequencies	at	D28	after	vaccination	were	304	
and	673	SFC	after	ChAd63‐MVA	CS	or	ME‐TRAP	respectively,	and	at	D63	peaked	
at	1378	and	2068	SFC	after	ChAd63‐MVA	CS	or	ME‐TRAP	respectively.	ChAd63	=	
Simian	adenovirus	63;	MVA	=	Modified	Vaccinia	virus	Ankara;	CS	=	
Circumsporozoite;	ME‐TRAP	=	Multiple	epitope	‐	thrombospondin‐related	
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adhesion	protein;	CHMI	=	controlled	human	malaria	infection;	Controls	=	
unvaccinated	volunteers	undergoing	CHMI;	SFC	=	spot	forming	cells	per	million	
peripheral	blood	mononuclear	cells.	
	
Figure	3.	Antibody	responses	to	vaccination	measured	by	ELISA	(A)	Anti‐CS	
IgG	antibody	responses	after	vaccination	with	ChAd63‐MVA	CS	(Group	1;	red)	or	
ME‐TRAP	(Group	2;	blue).	Lines	represent	group	medians.	***	=	p=<0.001;	*	=	
p=<0.05;	Friedman	test	comparing	pre‐	and	post‐vaccination	responses	with	
Dunn’s	post‐test.	(B)	Anti‐TRAP	IgG	antibody	responses	after	vaccination	with	
ChAd63	ME‐TRAP	(Group	2);	***	=	p=0.0002,	2‐tailed	Wilcoxon	matched	pairs	
test.	(C)	Correlation	between	anti‐CS	IgG	antibodies	and	CS‐specific	T	cell	
immunogenicity	the	day	before	challenge	in	Group	1;	r=0.5,	p=0.08;	Spearman	
rank.	EU	=	ELISA	units;	ME‐TRAP	=	Multiple	epitope‐thrombospondin‐related	
adhesion	protein;	CS	=	circumsporozoite	protein;	ChAd63	=	simian	adenovirus	
63;	MVA	=	Modified	Vaccinia	virus	Ankara;	CHMI	=	controlled	human	malaria	
infection;	Controls	=	unvaccinated	volunteers	undergoing	CHMI.		
	
Figure	4.	Efficacy	of	ChAd63‐MVA	CS	&	ME‐TRAP	immunization	following	P.	
falciparum	3D7	sporozoite	challenge.	Kaplan‐Meier	survival	analyses.	Log‐
Rank	test	for	significance.	(A)	Kaplan‐Meier	survival	analysis	of	time	to	
treatment	in	days.	Median	time	=	12.0	days	for	Group	1	(CS),	12.5	days	for	Group	
2	(ME‐TRAP)	and	10.3	days	for	unvaccinated	controls.	(B)	Kaplan‐Meier	survival	
analysis	of	time	to	first	positive	qPCR	sample	>	500	parasites/mL.	Median	time	=	
10.5	days	for	Group	1	(CS),	12.0	days	for	Group	2	(ME‐TRAP)	and	7.5	days	for	
unvaccinated	controls.	(C)	Kaplan‐Meier	survival	analysis	of	time	to	first	positive	
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qPCR	sample	>	20	parasites/mL.	Median	time	=	7.5	days	for	Group	1	(CS),	9.0	
days	for	Group	2	(ME‐TRAP)	and	7.0	days	for	unvaccinated	controls.	CS	=	
circumsporozoite	protein;	ME‐TRAP	=	Multiple	epitope‐thrombospondin	related	
adhesion	protein.	Controls	=	unvaccinated	volunteers	undergoing	controlled	
human	malaria	infection	(CHMI);	qPCR	=	P.	falciparum	quantitative	polymerase	
chain	reaction.		
	
Figure	5.	Comparison	of	Mean	Parasite	Density	measured	by	qPCR	at	7.5	
days	post	CHMI	between	Vaccinees	and	Control	Volunteers.	Mann	Whitney	
test.	Group	1	=	ChAd63‐MVA	CS;	Group	2	=	ChAd63	ME‐TRAP;	Control	=	
Unvaccinated	volunteers	undergoing	controlled	human	malaria	infection.	CS	=	
circumsporozoite	protein;	ME‐TRAP	=	Multiple	epitope‐thrombospondin	related	
adhesion	protein.		
	
Figure	6:	Comparison	of	Area	Under	the	Curve	of	parasite	Densities	
measured	by	qPCR	between	Vaccinees	and	Control	Volunteers.	(A)	Group	
mean	log	transformed	PCR	data.	The	area	under	the	curve	(AUC)	of	parasite	
density	over	the	ﬁrst	three	replication	cycles	in	infected	volunteers	signiﬁcantly	
predicted	time	to	diagnosis	(Cox	proportional	hazards	regression;	HR=1.000015	
(1.000008	–	1.000022),	p<0.000).	(B)	Area	under	curve	analysis	of	parasite	
densities	comparing	controls	to	vaccinees	at	days	6.5‐8	(first	cycle	post	
hepatocyte	release),	days	8.5‐10	(second	cycle)	and	10.5‐12	(third	cycle)	post	
CHMI.	Means	of	log	(parasite	density+1)	were	compared	for	each	vaccine	group	
to	controls	using	a	2‐tailed	t	test.	ChAd63	=	simian	adenovirus	63;	MVA	=	
Modified	Vaccinia	virus	Ankara;	CS	=	circumsporozoite	protein;	ME=TRAP	=	
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Multiple	epitope‐thrombospondin	related	adhesion	protein;	Controls	=	
unvaccinated	volunteers	undergoing	CHMI;	SP	=	sterilely	protected.	1st	–	1st	
blood‐stage	replication	cycle,	2nd	=	2nd	blood‐stage	replication	cycle,	3rd	=	3rd	
blood‐stage	replication	cycle.		
	
Figure	7:	Associations	between	immunological	outcomes	and	vaccine	
efficacy.	Correlation	between	parasite	density	at	day	7.5	(parasite/mL	measured	
by	qPCR)	and	levels	of	anti‐CS	IgG	antibody	(μg/mL)	in	(A)	Group	1	(CS);	
Spearman	rank	r=‐0.6,	p=0.03	and	(B)	Group	2	(ME‐TRAP);	Spearman	rank	r=‐0.3,	
p=0.34.	(C)	Correlation	between	parasite	density	at	day	7.5	(parasite/mL	
measured	by	qPCR)	and	anti‐TRAP	IgG	antibody	responses	(ELISA	units)	in	
Group	2	(ME‐TRAP);	Spearman’s	r=‐0.5,	p=0.05.	(D)	Correlation	between	IFNγ‐
secreting	T	cell	frequency	to	CS	measured	by	ELISPOT	parasite	density	at	day	7.5	
(parasite/mL	measured	by	qPCR)in	Group	1	(CS);	Spearman	rank	r=‐0.2,	p=0.50.	
(E)	Correlation	between	IFNγ‐secreting	T	cell	frequency	to	ME‐TRAP	measured	
by	ELISPOT	and	time	to	diagnosis	(days)	in	Group	2	(ME‐TRAP);	Spearman	rank	
r=0.1,	p=0.6.	Group	1	=	ChAd63‐MVA	CS;	Group	2	=	ChAd63‐MVA	ME‐TRAP;	CS	=	
circumsporozoite	protein;	ME‐TRAP	=	Multiple	epitope‐thrombospondin	related	
adhesion	protein;	EU	=	ELISA	units;	SFC	=	spot	forming	colonies	per	million	
peripheral	blood	mononuclear	cells;	Black	filled	points	=	sterilely	protected	
vaccinees;	Unfilled	points	=	vaccinees	demonstrating	delay	to	start	of	
antimalarial	therapy	in	comparison	to	unvaccinated	control	volunteers.		
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